Eiko Lifesciences Ltd
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
- Market Cap ₹ 69.7 Cr.
- Current Price ₹ 50.8
- High / Low ₹ 74.9 / 42.0
- Stock P/E 37.0
- Book Value ₹ 45.6
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.11 times its book value
- Promoter holding has increased by 4.96% over last quarter.
Cons
- Promoter holding is low: 36.2%
- Earnings include an other income of Rs.1.06 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | |
---|---|---|---|---|
2.36 | 4.27 | 10.81 | 37.66 | |
1.98 | 4.95 | 15.29 | 34.90 | |
Operating Profit | 0.38 | -0.68 | -4.48 | 2.76 |
OPM % | 16.10% | -15.93% | -41.44% | 7.33% |
0.04 | 0.04 | 0.09 | 1.06 | |
Interest | 0.09 | 0.19 | 0.35 | 0.16 |
Depreciation | 0.08 | 0.17 | 0.19 | 0.74 |
Profit before tax | 0.25 | -1.00 | -4.93 | 2.92 |
Tax % | 20.00% | -21.00% | -26.77% | 25.68% |
0.20 | -0.78 | -3.62 | 2.32 | |
EPS in Rs | 0.31 | -0.69 | -2.98 | 1.69 |
Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 28% |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 24% |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 42% |
3 Years: | 6% |
1 Year: | -3% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | |
---|---|---|---|---|
Equity Capital | 3.82 | 3.82 | 3.82 | 13.76 |
Reserves | 1.74 | 1.10 | -0.87 | 43.03 |
1.74 | 1.37 | 1.61 | 2.77 | |
3.66 | 3.01 | 7.49 | 6.54 | |
Total Liabilities | 10.96 | 9.30 | 12.05 | 66.10 |
1.68 | 1.71 | 1.75 | 23.12 | |
CWIP | -0.00 | -0.00 | -0.00 | -0.00 |
Investments | 3.17 | 1.72 | 0.10 | 7.15 |
6.11 | 5.87 | 10.20 | 35.83 | |
Total Assets | 10.96 | 9.30 | 12.05 | 66.10 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | |
---|---|---|---|---|
-0.00 | 0.16 | -0.33 | 2.92 | |
-0.00 | -0.30 | -0.71 | -11.44 | |
-0.00 | -0.55 | 0.95 | 6.96 | |
Net Cash Flow | -0.00 | -0.69 | -0.09 | -1.57 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | |
---|---|---|---|---|
Debtor Days | 225.81 | 73.51 | 39.84 | 104.58 |
Inventory Days | 819.93 | 287.76 | 136.40 | 64.48 |
Days Payable | 605.69 | 174.40 | 163.59 | 36.99 |
Cash Conversion Cycle | 440.04 | 186.87 | 12.65 | 132.07 |
Working Capital Days | 267.56 | 78.64 | -145.86 | 151.10 |
ROCE % | -11.83% | -102.92% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 May - Newspaper Publication - Results Q4/ 2025-26 Board Meeting dated 14th May, 2025
-
Revised Financial Results For Quarter And Year Ended 31St March, 2025
14 May - Audited Q4 and FY25 financial results approved; unmodified audit opinion; new secretarial and internal auditors appointed.
-
Revise Outcome Of Board Meeting Dated 14.05.2025
14 May - Audited FY25 financial results approved; unmodified audit opinion; new secretarial and internal auditors appointed.
-
Appointment Of Secretarial Auditor
14 May - Appointment of M/s Shravan Gupta & Associates as secretarial auditor for 5 years from FY 2025-26.
-
Appointment Of Internal Auditor
14 May - Appointment of M/s NP Rajput & Co as internal auditor for FY 2025-26 on 14 May 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
ELL is in the business of manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and Fine Chemicals comprising organic & inorganic chemicals, and Pharma Intermediates, etc.